XCF Global, Inc.
SAFX Nasdaq Industrial Organic Chemicals Financials FY2024–FY2025
What XCF Global, Inc. does
No business description yet.
- Legal name
- XCF Global, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001493152-26-014280
0002019793
Revenue and margins
XCF Global, Inc. had $0.0M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
XCF Global, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably XCF Global, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $0.4M | $0.2M |
| Debt incl. finance leases | $0.2M | $124M |
| Debt / equity | 0.0x | 3.3x |
| Current ratio | 0.0x | 0.1x |
| Quick ratio | 0.0x | 0.1x |
| Total assets | $355M | $419M |
| Total liabilities | $313M | $382M |
| Shareholders' equity | $41.4M | $37.7M |
| Net debt (− = net cash) | −$0.2M | $124M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✓ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ |
| Debt fell relative to assets | — | ✕ |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | — |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | ✕ |
| F-score | — / 3 | 3 / 7 |
| Accruals ratio | −3.7% | 23.7% |
| Altman Z'' | −3.84 | −4.58 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $0.0M | $0.0M |
| Net interest income | −$2.9M | −$9.2M |
| Gross profit | — | −$3.8M |
| Operating income | −$21.2M | −$67.9M |
| Net income | −$24.1M | $74.0M |
| Diluted EPS | — | $0.52 |
| Diluted shares | — | 0.14B |
| Cash flow | ||
| Cash from operations | −$11.1M | −$17.9M |
| Capital expenditure | $28.7M | — |
| Free cash flow | −$39.8M | — |
| Stock-based compensation | $0.0M | $8.8M |
| Balance sheet | ||
| Cash and short-term investments | $0.4M | $0.2M |
| Total debt | $0.2M | $124M |
| Current assets | $1.4M | $27.6M |
| Current liabilities | $180M | $249M |
| Inventory | — | $0.3M |
| Property and equipment, net | $352M | $390M |
| Total assets | $355M | $419M |
| Total liabilities | $313M | $382M |
| Shareholders' equity | $41.4M | $37.7M |
| Returns | ||
| Return on capital | −40.6% | −33.2% |
| Return on capital employed | −12.2% | −39.8% |
| Return on equity | −58.2% | 187.1% |
| Return on assets | −6.8% | 19.1% |
| Return on tangible equity | −58.2% | 196.6% |
| Financial health | ||
| Debt / equity | 0.0x | 3.3x |
| Current ratio | 0.0x | 0.1x |
| Quick ratio | 0.0x | 0.1x |
| Quality scores | ||
| Piotroski F-score | — | 3.0 |
| Altman Z'' | −3.8 | −4.6 |
| Accruals ratio | −3.7% | 23.7% |
Source: SEC EDGAR XBRL filings (CIK 0002019793). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.